|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
US20030229058A1
(en)
*
|
2001-11-13 |
2003-12-11 |
Moran Edmund J. |
Aryl aniline beta2 adrenergic receptor agonists
|
|
TWI249515B
(en)
*
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
|
US6653323B2
(en)
*
|
2001-11-13 |
2003-11-25 |
Theravance, Inc. |
Aryl aniline β2 adrenergic receptor agonists
|
|
KR100693367B1
(ko)
|
2002-06-27 |
2007-03-12 |
아스텔라스세이야쿠 가부시키가이샤 |
아미노알콜 유도체
|
|
AR040661A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Theravance Inc |
Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
|
|
PE20050130A1
(es)
*
|
2002-08-09 |
2005-03-29 |
Novartis Ag |
Compuestos organicos
|
|
ATE552236T1
(de)
|
2003-01-14 |
2012-04-15 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
|
|
PE20040950A1
(es)
*
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
JP4767842B2
(ja)
*
|
2003-04-01 |
2011-09-07 |
セラヴァンス， インコーポレーテッド |
β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
|
|
EP1622875B1
(en)
*
|
2003-05-08 |
2009-12-02 |
Theravance, Inc. |
Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
|
|
TW200510277A
(en)
*
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
|
DE602004021921D1
(de)
*
|
2003-05-28 |
2009-08-20 |
Theravance Inc |
Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
|
|
US7375100B2
(en)
|
2003-06-04 |
2008-05-20 |
Pfizer Inc |
2-amino-pyridine derivatives useful for the treatment of diseases
|
|
GB0312832D0
(en)
*
|
2003-06-04 |
2003-07-09 |
Pfizer Ltd |
2-amino-pyridine derivatives useful for the treatment of diseases
|
|
AU2004264941B2
(en)
|
2003-08-11 |
2008-11-27 |
Glaxo Group Limited |
Pharmaceutical metered dose inhaler and methods relating thereto
|
|
US7504401B2
(en)
|
2003-08-29 |
2009-03-17 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents and uses thereof
|
|
TW200526547A
(en)
*
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
|
TW200531692A
(en)
*
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
EP1574501A1
(en)
*
|
2004-03-11 |
2005-09-14 |
Pfizer Limited |
Quinolinone derivatives, pharmaceutical compositions containing them and their use
|
|
WO2005092861A1
(en)
*
|
2004-03-11 |
2005-10-06 |
Pfizer Limited |
Quinolinone derivatives pharmaceutical compositions containing them and their use
|
|
GB0425054D0
(en)
*
|
2004-03-23 |
2004-12-15 |
Pfizer Ltd |
Formamide derivatives for the treatment of diseases
|
|
WO2005092841A1
(en)
*
|
2004-03-23 |
2005-10-06 |
Pfizer Limited |
Compounds having beta-agonist activity
|
|
WO2005092887A1
(en)
*
|
2004-03-23 |
2005-10-06 |
Pfizer Limited |
Compounds for the treatment of diseases
|
|
WO2005092860A1
(en)
*
|
2004-03-23 |
2005-10-06 |
Pfizer Limited |
Compounds for the treatment of diseases
|
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
|
CA2561400A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
CN1984876A
(zh)
*
|
2004-06-03 |
2007-06-20 |
施万制药 |
二胺类β2肾上腺素能受体激动剂
|
|
ES2522579T3
(es)
|
2004-06-17 |
2014-11-17 |
Cytokinetics, Inc. |
Compuestos, composiciones y métodos
|
|
GB0413960D0
(en)
*
|
2004-06-22 |
2004-07-28 |
Novartis Ag |
Organic compounds
|
|
WO2006014704A1
(en)
*
|
2004-07-21 |
2006-02-09 |
Theravance, Inc. |
DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
|
|
US7176222B2
(en)
|
2004-07-27 |
2007-02-13 |
Cytokinetics, Inc. |
Syntheses of ureas
|
|
WO2006023460A2
(en)
*
|
2004-08-16 |
2006-03-02 |
Theravance, Inc. |
COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
|
|
WO2006023457A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Theravance, Inc. |
COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
|
|
WO2006031556A2
(en)
*
|
2004-09-10 |
2006-03-23 |
Theravance. Inc. |
Amidine substituted aryl aniline compounds
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
WO2006051373A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
NZ556335A
(en)
*
|
2005-01-11 |
2009-07-31 |
Glaxo Group Ltd |
Cinnamate salts of a beta-2 adrenergic agonist
|
|
EP2484382A1
(en)
|
2005-03-30 |
2012-08-08 |
Schering Corporation |
Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
US8429052B2
(en)
*
|
2005-07-19 |
2013-04-23 |
Lincoln National Life Insurance Company |
Method and system for providing employer-sponsored retirement plan
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
JP2009504624A
(ja)
|
2005-08-08 |
2009-02-05 |
アージェンタ ディスカバリー リミテッド |
ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
WO2007045477A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Human antibodies against il-13 and therapeutic uses
|
|
EP1959947A2
(en)
*
|
2005-12-15 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
|
US20070208000A1
(en)
*
|
2005-12-15 |
2007-09-06 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
ES2419007T3
(es)
*
|
2005-12-15 |
2013-08-19 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y procedimientos
|
|
WO2007078815A2
(en)
*
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2007078839A2
(en)
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
GB0602778D0
(en)
*
|
2006-02-10 |
2006-03-22 |
Glaxo Group Ltd |
Novel compound
|
|
PT2322525E
(pt)
|
2006-04-21 |
2013-12-26 |
Novartis Ag |
Derivados de purina para utilização como agonistas do recetor de adenosina a2a
|
|
TW200811105A
(en)
*
|
2006-04-25 |
2008-03-01 |
Theravance Inc |
Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
TW200811104A
(en)
*
|
2006-04-25 |
2008-03-01 |
Theravance Inc |
Crystalline forms of a dimethylphenyl compound
|
|
GB0613154D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic Compounds
|
|
CA2657639A1
(en)
|
2006-07-19 |
2008-01-24 |
Astrazeneca Ab |
Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
|
|
ES2302447B1
(es)
*
|
2006-10-20 |
2009-06-12 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
ATE555111T1
(de)
|
2006-12-19 |
2012-05-15 |
Astrazeneca Ab |
Chinuclidinol-derivate als muscarinrezeptor- antagonisten
|
|
BRPI0722095A2
(pt)
*
|
2006-12-20 |
2014-04-01 |
Astrazeneca Ab |
Derivados de amina e seu uso em doenças mediadas por beta-2-adrenor-receptor
|
|
RS51644B
(sr)
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
MX2009008493A
(es)
|
2007-02-09 |
2009-08-20 |
Irm Llc |
Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
|
|
ES2306595B1
(es)
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
|
CN101687851B
(zh)
|
2007-05-07 |
2013-02-27 |
诺瓦提斯公司 |
有机化合物
|
|
ES2320961B1
(es)
*
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
|
CL2008003651A1
(es)
|
2007-12-10 |
2009-06-19 |
Novartis Ag |
Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
|
|
AU2009203693B2
(en)
|
2008-01-11 |
2012-06-07 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
|
EP2096105A1
(en)
*
|
2008-02-28 |
2009-09-02 |
Laboratorios Almirall, S.A. |
Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
|
|
EA017627B1
(ru)
|
2008-05-13 |
2013-01-30 |
Астразенека Аб |
Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
|
|
MX2010012492A
(es)
|
2008-05-27 |
2010-12-21 |
Astrazeneca Ab |
Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
|
|
CA2727196A1
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Organic compounds
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
|
MX2011007036A
(es)
|
2008-12-30 |
2011-07-20 |
Pulmagen Therapeutics Inflammation Ltd |
Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
|
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
|
MX2011011446A
(es)
*
|
2009-04-30 |
2011-11-18 |
Teijin Pharma Ltd |
Compuestos de sal de amonio cuaternario.
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
EP2455802A4
(en)
|
2009-07-15 |
2013-01-16 |
Sharp Kk |
LIQUID CRYSTAL DISPLAY DEVICE
|
|
US20110098311A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorported |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
WO2011061527A1
(en)
|
2009-11-17 |
2011-05-26 |
Astrazeneca Ab |
Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
GB201016912D0
(en)
|
2010-10-07 |
2010-11-24 |
Astrazeneca Ab |
Novel combination
|
|
MA34969B1
(fr)
|
2011-02-25 |
2014-03-01 |
Irm Llc |
Composes et compositions en tant qu inibiteurs de trk
|
|
CN102199099B
(zh)
*
|
2011-04-11 |
2013-12-18 |
常州大学 |
3-溴-4-甲氧基苯胺的制备方法
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
ES2882807T3
(es)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
Heterociclil carboxamidas N-sustituidas
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
BR112016024484A2
(pt)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
|
|
US9862711B2
(en)
|
2014-04-24 |
2018-01-09 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
EP3190103A1
(en)
*
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
|
US11866482B2
(en)
|
2018-02-07 |
2024-01-09 |
Duke University |
System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators
|
|
AU2020290094B2
(en)
|
2019-06-10 |
2024-01-18 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
|
|
AU2020338971B2
(en)
|
2019-08-28 |
2023-11-23 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
|
CN110698352B
(zh)
*
|
2019-10-29 |
2023-01-17 |
邢台学院 |
一种3-溴-5-氨基邻苯二酚二甲醚的合成方法
|